Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuraxis (NRXS) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Neuraxis (NRXS) over the last 4 years, with Q3 2025 value amounting to $1.3 million.

  • Neuraxis' Gains from Investment Securities rose 1951632.47% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 30394.16%. This contributed to the annual value of $1.3 million for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that Neuraxis reported Gains from Investment Securities of $1.3 million as of Q3 2025, which was up 1951632.47% from $1.3 million recorded in Q2 2025.
  • Neuraxis' Gains from Investment Securities' 5-year high stood at $1.3 million during Q1 2024, with a 5-year trough of -$1.3 million in Q4 2022.
  • Over the past 4 years, Neuraxis' median Gains from Investment Securities value was $4228.0 (recorded in 2024), while the average stood at $228319.4.
  • In the last 5 years, Neuraxis' Gains from Investment Securities crashed by 75416.1% in 2023 and then soared by 1951632.47% in 2025.
  • Neuraxis' Gains from Investment Securities (Quarter) stood at -$1.3 million in 2022, then surged by 95.8% to -$53244.0 in 2023, then surged by 103.25% to $1730.0 in 2024, then skyrocketed by 76165.55% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $1.3 million for Q2 2025, and $1.3 million during Q1 2025.